Amgen Realigns Aranesp Pricing Policy

BMI expects shaky sales for Amgen's key biotech offering Aranesp (darbepoetin alfa), after the company decided to discontinue discounts on the biotech product in response to heightened safety concerns, according to a report in the New York Times. Amgen is to end the practice of offering rebates to oncology clinics if they use Aranesp from October, but has pledged to continue to offer bulk discounts on the

To read the full article, please choose one of the following options: